• Scotiabank sets a price target of $39 for NASDAQ:LINE, indicating a potential upside of approximately 7.04%.
• Lineage Cell Therapeutics announces a significant milestone in its collaboration with Factor Bioscience Inc., receiving a novel induced pluripotent stem cell (iPSC) line with hypoimmunity edits.
• The current trading price of LINE is $36.55, with a year's fluctuation between $62.30 and $32.45, highlighting its market volatility.

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX) is a clinical-stage biotechnology company focused on developing innovative cell therapies. The company is currently trading on the NASDAQ under the symbol NASDAQ:LINE. On January 9, 2026, Scotiabank set a price target of $39 for LINE, while the stock was trading at $36.44, indicating a potential upside of approximately 7.04%.

Recently, Lineage announced a significant milestone in its collaboration with Factor Bioscience Inc. The company successfully received a novel induced pluripotent stem cell (iPSC) line with hypoimmunity edits. This development is crucial for their strategic partnership, which aims to create allogeneic, or "off the shelf," cell therapies for serious medical conditions.

The current price of LINE is $36.55, reflecting a slight decrease of 0.02, or approximately -0.05%. Today, the stock has fluctuated between a low of $35.70 and a high of $37.08. Over the past year, LINE has seen a high of $62.30 and a low of $32.45, showcasing its volatility in the market.

Lineage's market capitalization is approximately $8.35 billion, with a trading volume of 365,212 shares. This indicates a moderate level of investor interest and activity in the stock. The company's recent developments and strategic collaborations may influence its future performance and investor sentiment.